Articles tagged with: Immunology

Killer cell immunotherapy shows promise for advanced pancreatic cancer

Posted in General News, Publications Published by Bethan Warman 01 November 2018

Killer cell immunotherapy shows promise for advanced pancreatic cancer

A new approach to treating pancreatic cancer using 'educated killer cells' has shown promise, according to early research from the BCI. The new cell-based immunotherapy, which has not yet been tested in humans with pancreatic cancer, led to mice being completely cancer-free.

New trial using combination therapy extends survival in triple-negative breast cancer

Posted in General News, BCI on the Road, Publications Published by Bethan Warman 22 October 2018

New trial using combination therapy extends survival in triple-negative breast cancer

New research led by Barts Cancer Institute and St Bartholomew’s Hospital has provided new hope for people with an aggressive type of breast cancer. The phase 3 clinical trial has shown that by using a combination of immunotherapy and chemotherapy, the body’s own immune system can be tuned to attack triple-negative breast cancer, extending survival by up to ten months.

Immunotherapy shows promise for patients with metastatic triple-negative breast cancer

Posted in General News, Publications Published by Bethan Warman 17 October 2018

Immunotherapy shows promise for patients with metastatic triple-negative breast cancer

Immunotherapy has been shown to confer an encouraging survival benefit in patients with metastatic triple-negative breast cancer (mTNBC). The phase 1 clinical trial, led by Prof Peter Schmid, Centre Lead for BCI’s Centre for Experimental Cancer Medicine, is the first to report the long-term safety and efficacy of the drug for mTNBC, and may represent significant steps forward for treatment of this disease.

Blood Cancer Awareness Month 2018

Posted in General News Published by Bethan Warman 28 September 2018

Blood Cancer Awareness Month 2018

Blood Cancer Awareness Month takes place every September to raise awareness of the challenges faced by those living with blood cancer. In the UK, blood cancer is the fifth most common cancer, with 240,000 people living with the disease and 38,000 people being diagnosed with a type of blood cancer each year. The three main blood cancer types are leukaemia, lymphoma and myeloma; however, there are over 100 individual types.

Pancreatic Cancer UK Grand Challenge

Posted in General News, Grants & Awards Published by Bethan Warman 27 July 2018

PCUK’s largest ever research fund

Pancreatic Cancer UK Grand Challenge

Our Director, Prof Nicholas Lemoine, and a team of researchers from the BCI and King’s College London have been awarded the Pancreatic Cancer UK (PCUK) Grand Challenge- PCUK’s largest ever research fund. The grant will be used for the development of a type of immunotherapy, known as CAR-T cell therapy, to treat pancreatic cancer.

Immunotherapy harnesses the body’s own immune system to identify and kill cancer cells, and has been demonstrated to be an effective treatment option in a variety of cancer types. In CAR-T cell therapy, T cells- key immune cells responsible for fighting infected cells- are isolated from patient blood samples, modified outside of the body and reinjected back into the patient. Once back in the body, the T cells are equipped to target and attack tumours.

London Pancreas Workshop 2018

Posted in General News, BCI Spotlight Articles, Events Published by Bethan Warman 11 May 2018

A forum for state-of-the-art clinical and basic research in pancreatic cancer

London Pancreas Workshop 2018

On Friday 4th May, BCI hosted the seventh London Pancreas Workshop, co-organised by Prof Hemant Kocher and our Director Prof Nick Lemoine, which attracted delegates from across Europe and America, with over 140 attendees in total. The biennial event is recognised as a forum for state-of-the-art clinical and basic research in pancreatic cancer.

The areas of focus for this year’s workshop were diagnostics, clinical trials and preclinical work for targeting pancreatic cancer. We heard a variety of interesting talks in these areas, delivered by researchers renowned in their fields.

BCI and KCL collaboration develops a clinically-relevant CAR-T cell imaging system

Posted in General News, Publications Published by Bethan Warman 19 April 2018

BCI and KCL collaboration develops a clinically-relevant CAR-T cell imaging system

A collaboration involving researchers from BCI’s Centre for Molecular Oncology, led by Dr Jane Sosabowski, and the ImmunoEngineering Group of King’s College London (KCL), led by Dr Sophie Papa, has developed an effective and clinically-relevant imaging system to monitor chimeric antigen receptor (CAR)-T cells within the body. This system reduced the tumour burden in a pre-clinical model of prostate cancer and allowed for repeated and non-invasive assessment of CAR-T cell localisation.

Steps towards the development of a new immunotherapy for pancreatic cancer

Posted in General News, Publications Published by Bethan Warman 23 January 2018

Steps towards the development of a new immunotherapy for pancreatic cancer

A research team led by Professor Yaohe Wang at the Barts Cancer Institute (BCI) of Queen Mary University of London (QMUL) has created a novel oncolytic viral agent expressing interleukin-12 (IL-12) that shows promise as a potential anti-tumour immunotherapy for the treatment of pancreatic cancer.

Using hamster models of pancreatic cancer that closely mimic the stages of tumour development in humans, the study demonstrated that treatment with the virus expressing a modified form of IL-12 could result in up to 100 per cent tumour eradication and survival.

BCI at the 59th ASH Annual Meeting

Posted in General News, Conferences, BCI on the Road Published by Reza Roozitalab 08 December 2017

"The most prestigious event in the haematology calendar"

BCI at the 59th ASH Annual Meeting

Research teams from our Centre for Haemato-Oncology have once again joined the world’s most influential figures in haematology to present their cutting-edge findings at the 59th ASH Annual Meeting & Exposition.

Dr Peter Szlosarek at the 18th IASLC World Conference on Lung Cancer

Posted in Conferences, BCI on the Road Published by Reza Roozitalab 17 October 2017

ADI-PEG20 with Immune Checkpoint Blockade for Malignant Mesothelioma

Dr Peter Szlosarek at the 18th IASLC World Conference on Lung Cancer

Tomorrow, Wednesday 18th October, Dr Peter Szlosarek will present "Pegylated Arginine Deiminase Potentiates PD-1/PDL-1 Immune Checkpoint Blockade in Malignant Mesothelioma" at the 18th IASLC World Conference on Lung Cancer, Yokohama, Japan...

This site uses cookies in order to function properly. By continuing to browse, you agree that we can save them on your device. Privacy Policy.